PCI Biotech - release of the RNA Therapeutics Virtual Conference presentation
10 févr. 2021 02h31 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 10 February 2021 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today released...
PCI Biotech to present at RNA Therapeutics Virtual Conference
22 janv. 2021 06h04 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 22 January 2021 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced...
PCI Biotech: Successful Phase I fimaVacc vaccination proof of concept study to be published in Frontiers in Immunology
23 nov. 2020 02h30 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 23 November 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that the results from the successful Phase I proof of concept study for the...
PCI Biotech: European patent for treatment of bile duct cancer with the fimaChem technology
16 nov. 2020 02h30 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 16 November 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces that the European Patent Office (EPO) has informed the company that a new...
PCI Biotech third quarter 2020 results
11 nov. 2020 01h00 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 11 November 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim Q3 2020 results. Please find enclosed the report and presentation. ...
PCI Biotech: Invitation to third quarter 2020 results presentation
04 nov. 2020 03h15 HE
|
PCI Biotech Holding ASA
Oslo, Norway, 4 November 2020 - PCI Biotech’s (OSE: PCIB) third quarter 2020 interim report will be released on 11 November 2020 at 07.00 CET. The interim report and presentation will be made...
PCI Biotech: First patient enrolled in Asia in the fimaCHEM pivotal RELEASE study
26 oct. 2020 07h48 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 26 October 2020 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced...
PCI Biotech: Preclinical research collaboration with big pharma ended
21 oct. 2020 02h30 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 21 October 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today informed that AstraZeneca has elected not to enter into a definitive agreement for the...
PCI Biotech: Employee share option scheme
06 oct. 2020 09h02 HE
|
PCI Biotech Holding ASA
Oslo, 06 October 2020 In accordance with the authorisation granted by the Annual General Meeting 27 May 2020, the Board of Directors of PCI Biotech Holding ASA has awarded a total of 540,000 share...
PCI Biotech: Capital increase registered and listing of new shares
08 sept. 2020 06h00 HE
|
PCI Biotech Holding ASA
Oslo, Norway, 8 September 2020. Reference is made to the previous announcements by PCI Biotech Holding ASA ("PCI Biotech" or the "Company") in respect of the issuance of 60,500 new shares following...